Ocular Therapeutix（納斯達克代碼：OCUL）報告其季度每股虧損爲$(0.29)，低於分析師普遍預期的$(0.24)，差異爲20.83%。與去年同期每股虧損$(0.35)相比，這一數字增加了17.14%。該公司報告季度銷售額爲1708萬美元，低於分析師普遍預期的1720萬美元，差異爲0.71%。與去年同期的1480萬美元銷售額相比，這一數字增加了15.41%。

以上內容來自Benzinga Earnings專欄，原文如下：

Ocular Therapeutix (NASDAQ:OCUL) reported quarterly losses of $(0.29) per share which missed the analyst consensus estimate of $(0.24) by 20.83 percent. This is a 17.14 percent increase over losses of $(0.35) per share from the same period last year. The company reported quarterly sales of $17.08 million which missed the analyst consensus estimate of $17.20 million by 0.71 percent. This is a 15.41 percent increase over sales of $14.80 million the same period last year.